Skip to main content

Table 1 Baseline clinical characteristics in patients with and without VDRA therapy

From: Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study

Clinical characteristic Total VDRA P-value
Yes No
General     
N (%) 568 389 (68.5) 179 (31.5)  
Gender (male), n (%) 389 (68.5) 260 (66.9) 129 (72.1)  
Median age (IQR), years 70 (57–77) 69 (56–76.5) 70 (60–77) 0.31
Median height (IQR), cn 165 (160–170) 165 (160–171) 167 (160–170) 0.89
BMI (Kg/M2) 23.5 (21.2-26.4) 23.5 (21.2-26.3) 23.4 (20.8-26.5) 0.47
Comorbid diseases     
Hypertension, n (%) 496 (87.3) 347 (89.2) 149 (83.2) 0.05
Cardiovascular disease, n (%) 338 (59.5) 233 (59.9) 105 (58.7) 0.78
Vascular disease, n (%) 277 (48.8) 188 (48.3) 89 (49.7) 0.6
Diabetes, n (%) 164 (28.9) 109 (28) 55 (30.7) 0.52
Dyslipidemia, n (%) 104 (18.3) 164 (42.2) 61 (34.1) 0.07
Liver disease, n (%) 54 (9.5) 42 (10.8) 12 (6.7) 0.12
  1. BMI = body mass index.
  2. IQR = interquartile range.
  3. Statistically significant p-values are highlighted in bold.